DE602004031221D1 - Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung - Google Patents

Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung

Info

Publication number
DE602004031221D1
DE602004031221D1 DE602004031221T DE602004031221T DE602004031221D1 DE 602004031221 D1 DE602004031221 D1 DE 602004031221D1 DE 602004031221 T DE602004031221 T DE 602004031221T DE 602004031221 T DE602004031221 T DE 602004031221T DE 602004031221 D1 DE602004031221 D1 DE 602004031221D1
Authority
DE
Germany
Prior art keywords
preparation
tetrahydrocannabinol
delta
cannabinoid derivatives
cannabinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004031221T
Other languages
German (de)
English (en)
Inventor
Bob M Moore
Antonio M Ferreira
Mathangi Krishnamurthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of DE602004031221D1 publication Critical patent/DE602004031221D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE602004031221T 2003-05-20 2004-05-20 Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung Expired - Lifetime DE602004031221D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47231603P 2003-05-20 2003-05-20
PCT/US2004/015885 WO2004113320A1 (en) 2003-05-20 2004-05-20 Cannabinoid derivatives, methods of making, and use thereof

Publications (1)

Publication Number Publication Date
DE602004031221D1 true DE602004031221D1 (de) 2011-03-10

Family

ID=33539041

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004031221T Expired - Lifetime DE602004031221D1 (de) 2003-05-20 2004-05-20 Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung

Country Status (10)

Country Link
US (2) US7169942B2 (https=)
EP (1) EP1633733B1 (https=)
JP (1) JP2007501279A (https=)
CN (1) CN1809552A (https=)
AT (1) ATE496901T1 (https=)
AU (1) AU2004249669B2 (https=)
CA (1) CA2526103A1 (https=)
DE (1) DE602004031221D1 (https=)
DK (1) DK1633733T3 (https=)
WO (1) WO2004113320A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1727900A4 (en) * 2004-03-26 2008-05-28 Fujifilm Corp METHOD FOR SELECTIVELY SEPARATING AND CLEANING RNA, AND METHOD FOR SEPARATING AND CLEANING NUCLEIC ACID
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
USRE46558E1 (en) 2005-04-28 2017-09-26 Paloma Pharmaceuticals, Inc. Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
CN102766128A (zh) * 2005-09-29 2012-11-07 阿尔巴尼分子研究公司 δ-9-四氢大麻酚的生成方法
DE102005062098A1 (de) * 2005-12-22 2007-06-28 Merck Patent Gmbh Oxaphenanthren-Derivate
BRPI0708318A2 (pt) * 2006-02-28 2011-05-24 Paloma Pharmaceuticals, Inc. composições e uso de compostos para tratar doenças caracterizadas por proliferação celular e angiogênese
WO2008109027A2 (en) 2007-03-02 2008-09-12 University Of Tennessee Research Foundation, The Tri-aryl/heteroaroaromatic cannabinoids and use thereof
US20110021618A1 (en) * 2008-03-25 2011-01-27 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
JP2011520972A (ja) * 2008-05-19 2011-07-21 ユニヴァーシティ オブ テネシー リサーチ ファウンデーション，ザ ピリジンの古典的カンナビノイド化合物及び関連する使用方法
US8158654B2 (en) 2008-05-19 2012-04-17 The University Of Tennessee Research Foundation Pyridine non-classical cannabinoid compounds and related methods of use
US8022078B2 (en) * 2008-05-19 2011-09-20 University Of Tennessee Research Foundation Pyrimidine classical cannabinoid compounds and related methods of use
US8476439B2 (en) 2008-05-19 2013-07-02 The University Of Tennessee Research Foundation Pyridine classical cannabinoid compounds and related methods of use
WO2009143183A1 (en) * 2008-05-19 2009-11-26 University Of Tennessee Research Foundation, The Pyrimidine non-classical cannabinoid compounds and related methods of use
US8349876B2 (en) * 2008-05-19 2013-01-08 The University Of Tennesee Research Foundation Pyridine non-classical cannabinoid compounds and related methods of use
US8389534B2 (en) * 2008-05-19 2013-03-05 The University Of Tennessee Research Foundation Pyrimidine non-classical cannabinoid compounds and related methods of use
US9623000B2 (en) 2008-07-31 2017-04-18 Dekel Pharmaceuticals Ltd Compositions and methods for treating inflammatory disorders
WO2012112791A1 (en) 2011-02-16 2012-08-23 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
CN103110582A (zh) * 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
US20170008869A1 (en) * 2015-07-10 2017-01-12 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
IL248149B (en) * 2016-09-29 2020-03-31 Garti Nissim Dilutable formulations of cannbinoids and processes for their preparation
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US20180169061A1 (en) * 2016-12-15 2018-06-21 Ascent Pharmaceuticals, Inc. Non-aqueous delta9-tetrahydrocannabinol oral liquid formulations
WO2019045994A1 (en) * 2017-08-27 2019-03-07 Rhodes Technologies PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
WO2020041322A1 (en) 2018-08-20 2020-02-27 Berkowitz Barry A Novel cannabinoids and cannabinoid acids and their derivatives
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
CN110269839A (zh) * 2019-06-15 2019-09-24 云南飞久逍科技有限公司 一种大麻二酚cbd及其纳米乳在荨麻疹或/和鼻炎制剂中的应用
JP7770688B2 (ja) * 2019-10-03 2025-11-17 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド リポソームカンナビノイドおよびその使用
AU2020377914A1 (en) 2019-11-08 2022-06-02 Vella Bioscience, Inc. Peripherally acting cannabidiol(CBD)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941782A (en) * 1972-04-27 1976-03-02 Sharps Associates Heterocyclic esters of benzopyrans
US3915996A (en) * 1972-10-16 1975-10-28 Abbott Lab Process for making benzopyrans
US3901926A (en) * 1973-04-02 1975-08-26 Abbott Lab Alkylphenyl benzopyrans
DE4100441A1 (de) * 1991-01-09 1992-07-16 Mack Chem Pharm Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
DE69822449T2 (de) * 1997-01-21 2005-01-27 Smithkline Beecham Corp. Neue cannabinoidrezeptor-modulatoren
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
DE19706903A1 (de) * 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
EP0979228A4 (en) * 1997-03-18 2000-05-03 Smithkline Beecham Corp CANNABINOID RECEPTOR AGONISTS
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
WO1999057106A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US6563009B1 (en) * 1999-07-12 2003-05-13 Virginia Commonwealth University Vasodilator cannabinoid analogs
FR2799124B1 (fr) * 1999-10-01 2004-08-13 Sanofi Synthelabo Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US20040039048A1 (en) * 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
WO2001058869A2 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
US6448288B1 (en) * 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
EP1299374B1 (en) * 2000-06-22 2006-12-27 Pharmos Corporation Novel non-psychotropic cannabinoids
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
RU2004117907A (ru) * 2001-11-14 2006-01-10 Шеринг Корпорейшн (US) Лиганды каннабиноидных рецепторов
MXPA04012704A (es) * 2002-06-19 2005-03-23 Schering Corp Agonistas de los receptores canabinoides.
AU2003267728A1 (en) * 2002-10-18 2004-05-04 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
EP1633733A4 (en) 2007-02-28
CN1809552A (zh) 2006-07-26
US20040242593A1 (en) 2004-12-02
WO2004113320A1 (en) 2004-12-29
EP1633733B1 (en) 2011-01-26
US7169942B2 (en) 2007-01-30
JP2007501279A (ja) 2007-01-25
AU2004249669B2 (en) 2008-05-22
ATE496901T1 (de) 2011-02-15
DK1633733T3 (da) 2011-05-16
US20070167514A1 (en) 2007-07-19
EP1633733A1 (en) 2006-03-15
AU2004249669A1 (en) 2004-12-29
CA2526103A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
DE602004031221D1 (de) Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung
NO20010446L (no) Substituert anilidforbindelser og metoder
BR9914526A (pt) Derivados de adenina
BR0015962A (pt) Compostos tendo ligações multiplas que são agonistas de receptor adrenérgico (beta)2 úteis no tratamento e prevenção de doenças respiratórias
TR199801348T2 (xx) Heterosikl-kondanse morfinoid t�revleri(II).
EA199700156A1 (ru) Производные индола как антагонисты рецептора 5-нт
NO20003550L (no) Farmasøytiske sammensetninger og anvendelse herav
NO983431D0 (no) Anti-kl°emidler
ATE338565T1 (de) Verwendung eines antagonisten antikörpers gegen den entzündungsmediator oncostatin m (osm)
ATE144773T1 (de) Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne
ATE234322T1 (de) A1 adenosin rezeptor agonisten und antagonisten
DK1199069T3 (da) Anvendelse af en estrogenagonist/-antagonist til forbedring eller bibeholdelse af urogenital sundhed
DE69133135D1 (de) Menschliche neuronale nikotin-acetylcholin-rezeptor-verbindungen und methoden ihres einsatzes
ATE239823T1 (de) Verffahren und vorrichtung zur steuerung der papiereigenschaften
AU5614198A (en) Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
DK0639275T3 (da) Hidtil ukendte GABAa-receptorundertyper og fremgangsmåder til screening af lægemiddelforbindelser under anvendelse af imidazoquinoxaliner og pyrrolopyimidiner til binding til GABAa-receptorundertyper
DE60103856D1 (de) Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
BR0307903A (pt) derivados de arilsulfona
ATE254122T1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
ATE273389T1 (de) Rezeptor des y-y5 neuropeptids
DE50209113D1 (de) 1-allyl-ergotalkaloid-derivate- verfahren zu ihrer herstellung und ihre verwendung zur prophylaxe und therapie von migräne
BRPI0520579A2 (pt) composto, processo para a preparação de um composto, método para o tratamento de uma desordem do sistema nervoso central relacionada a ou afetada pelo receptor 5-ht6, composição farmacêutica, uso do composto e método para testar antagonistas e antagonistas com seletividade para o receptor 5-ht6
Feuerstein et al. Endogenous agonists may change the concentration-response curves of exogenous agonists: source of quantitative information about the endogenous tone
BR0307584A (pt) Pirimidinonas e pirimidinationas substituìdas
ATE239019T1 (de) Pyrido(2,3-b)indolizinderivate und aza analoge: crf1 spezifische liganden